PD-1 immunotherapy for recurrent or metastatic HNSCC
Mené dans 37 pays sur 882 patients atteints d'un carcinome épidermoïde de la tête et du cou de stade métastatique ou récidivant, cet essai de phase III compare l'efficacité, du point de vue de la survie globale et de la survie sans progression, et la toxicité du pembrolizumab, seul ou en combinaison avec une chimiothérapie, et du cétuximab en combinaison avec une chimiothérapie
Checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and PD-1 ligand 1 (PD-L1) pathway have drastically changed treatment and improved outcomes across numerous solid tumours in the past 5 years. Both nivolumab and pembrolizumab were approved in 2016 for the treatment of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC) that had progressed after platinum-based chemotherapy. This change has led to multiple trials evaluating anti-PD-1 and PD-L1 monoclonal antibodies for first-line treatment of recurrent or metastatic HNSCC, raising the questions of whether anti-PD-1 would replace, or perhaps integrate with, standard of care chemotherapy. The answer, in short, is yes to both questions.
The Lancet , commentaire, 2018